Inovio Pharmaceuticals, Inc.INONASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +13.97% | +0.00% | -100.00% | +0.00% | -155.85% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +19.16% | +16.61% | +42.77% | +85.39% | +1626.25% |
| Weighted Average Shares Diluted Growth | +19.16% | +16.61% | +42.77% | +85.39% | +1626.25% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -50.15% | -48.64% | -52.62% | -47.46% | -99.96% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -33.78% | -32.41% | -49.00% | -35.19% | +65546.53% |
| Book Value per Share Growth | -51.01% | -53.46% | -79.34% | +0.00% | -97.96% |
| Debt Growth | -60.72% | -16.06% | -17.89% | -19.49% | +78852.20% |
| R&D Expense Growth | -25.31% | -23.06% | -38.65% | -28.83% | +420244.56% |
| SG&A Expenses Growth | -32.21% | -14.63% | +91210.05% | -8.55% | +353007.41% |